Medical Insurance in Indiana, available through Acceptable Answers to Insurance, provides medical care for the diseases that are considered rare. These diseases, such as Huntington’s disease and Duchenne Muscular Dystrophy, affect fewer than 2000 people worldwide every year.
These rare diseases are also known as orphan diseases, or neglected diseases, because very little research is done in each of these diseases. They can also include rare cancers, certain congenital malformations, and autoimmune disorders, along with some infectious diseases. About 80% of the rare diseases identified at this time are due to genetic deficits.
There are a number of reasons that the orphan diseases are not researched as much as others. For one thing, these diseases are notoriously hard to diagnose, sometimes taking years to confirm diagnosis. Another drawback to research on these diseases is the extremely small patient pool. With fewer than 2000 patients, scattered all across the globe in various locales, it can be very hard to conduct sterile, controlled clinical studies. In addition, pharmaceutical companies have to make money to stay in business, and there’s not much profit in researching a rare disease that has such a limited market.
That’s why, when Rhenovia Pharma decided to incorporate orphan, rare, and neglected diseases into its research program, the science community sat up and took notice. Rhenovia Pharma is a biotech company that develops drugs used in neurogenerative, psychiatric, and neurological diseases. Specifically, Rhenovia Pharma will begin researching Huntington’s disease and Duchenne Muscular Dystrophy. Huntington’s disease is a fatal disease that caused neurodegenerative effects in the brain. It’s very hard to diagnose because of the variety of symptoms, most of which are easily confused with other diseases. Some of the symptoms are involuntary movement, psychiatric problems, and cognitive problems.
The president of Rhenovia Pharma, Dr. Serge Bischoff, said that his company’s method of testing and research – biostimulation – is the perfect platform for researching these rare diseases. In addition, the types of druge developed by Rhenovia promise to be a good jumping off place for the discovery and development of new drugs.
Rhenovia will be working with the French Association Against Myopathies, spurred on by what Dr. Bischoff called the “urgent need of DMD patients” for treatment. He believes that the line of drugs his company manufactures is going to be valuable in biosimulation studies, in which they hope to develop new strategies for treatments, especially in the dystrophies.
The last two years of research at Rhenovia’s laboratories have seen significant steps forward in simulating the deficits that accompany rare diseases, and the chemists, neuroscientists, and other researchers expect to see great gains in studies of neurodevelopmental disorders such as autism. Neurodegenerative diseases like Alzheimer’s are also predicted to see greater testing, as will psychiatric diseases such as schizophrenia. These diseases affect a much broader population and the researchers expect that as they work with the rare diseases, they will discover treatments for the more common ones, as well. As soon as the FDA approves each of the treatments, it will probably be covered by medical insurance in Indiana.
Our friendly insurance agents are here for you and are eager to help you find the best plan for you. Visit our website or call us toll free at (888) 355-7129.